Últimas publicaciones
- Mora J, Castañeda-Heredia A, Colombo MC, Gorostegui M, Fernando Gómez Muñoz, Mañe S, Santa-María López V, Garraus-Oneca M, Macias N, Pérez-Jaume S, Muñoz O, Muñoz JP, Ignacio Barber Martínez de la Torre and Suñol M Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma. Cancers . 13(6): .
- Rubio-San-Simón A, Verdú-Amorós J, Hladun R, Juan-Ribelles A, Molero M, Guerra-García P, Pérez-Martínez A, Castañeda-Heredia A, Cañete A, de Rojas T, Moreno L and Bautista F Challenges in early phase clinical trials for childhood cancer during the COVID-19 pandemic: a report from the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP). CLINICAL & TRANSLATIONAL ONCOLOGY . 23(1): 1-7.
- Rubio-San-Simón A, André N, Cefalo MG, Aerts I, Castañeda-Heredia A, Benezech S, Makin G, van Eijkelenburg N, Nysom K, Marshall L, Gambart M, Hladun R, Rossig C, Bergamaschi L, Fagioli F, Carpenter B, Ducassou S, Owens C, Øra I, Ribelles AJ, De Wilde B, Guerra-García P, Strullu M, Rizzari C, Ek T, Hettmer S, Gerber NU, Rawlings C, Diezi M, Palmu S, Ruggiero A, Verdú J, de Rojas T, Vassal G, Geoerger B, Moreno L and Bautista F Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium. EUROPEAN JOURNAL OF CANCER . 141: 82-91.